Notícias e Atividades da Ovid Therapeutics

Ovid Therapeutics é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Ovid Therapeutics é uma empresa listada sob o símbolo OVID (US).

Veja o organograma con seus 24 executivos principais

Biografias mais buscadas da Ovid Therapeutics

• Jeremy Levin, Chairman of the Board of Directors and Chief Executi...
• Barbara Duncan, Director
• Bart Friedman, Director

Recentes movimentos de executivos em Ovid Therapeutics

• Danielle Mann, Vice President, Legal and Compliance, deixou a Companhia  (Notícia publicada em 24 de março de 2025).
• Victoria Fort, ingressou na Companhia como Head, Corporate Affairs and Corporate Strategy  (Notícia publicada em 13 de março de 2025).
• Stelios Papadopoulos, ingressou na Companhia como Director  (Notícia publicada em 4 de março de 2025).

Clique aqui para ver outras movimentos em Ovid Therapeutics

Criar um alerta
para seguir os movimentos de executivos da Ovid Therapeutics.

Ovid Therapeutics possui 2.350 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Johnson & Johnson Innovative Medicine DIA (Estados Unidos).

Popular M&A news in Biotecnologia

• Transcarent and Accolade have merged  (publicado em 9 de abril de 2025)..
• Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
• Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Kristina Burow - Director da Scholar Rock
• Steven Gillis - Chairman of the Board da VBI Vaccines
• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Ovid Therapeutics

• Ovid Therapeutics to Host Educational Webinar on Angelman Syndrome and OV101 Development Program | Ovid Therapeutics Inc.Email-press-release
• Ovid Therapeutics to Present at the Child Neurology Society/International Child Neurology Association (CNS/ICNA) Virtual Congress | Ovid Therapeutics Inc.Email-press-release
• Ovid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare Epilepsies | Ovid Therapeutics Inc.Email-press-release
• Ovid Therapeutics to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference | Ovid Therapeutics Inc.Email-press-release
• Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome | Ovid Therapeutics Inc.Email-press-release
• Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock | Ovid Therapeutics Inc.Email-press-release
• Ovid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update | Ovid Therapeutics Inc.Email-press-release
• Ovid Therapeutics to Participate at the William Blair Biotech Focus Conference 2020 | Ovid Therapeutics Inc.Email-press-release
• Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic Therapy for Angelman Syndrome | Ovid Therapeutics Inc.Email-press-release
• Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in Europe | Ovid Therapeutics Inc.Email-press-release
• View more press releases Close

Redes sociais sobre Ovid Therapeutics

• Ovid Therapeutics na Wikipedia, Google News e Yahoo Finance
• Ovid Therapeutics na LinkedIn, Twitter e YouTube